The World Health Organization's (WHO) Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC) has made a crucial recommendation regarding the antigen composition of COVID-19 vaccines. In May 2026, the TAG-CO-VAC advised that monovalent LP.8.1 is the recommended vaccine antigen, aiming to enhance immune responses to circulating SARS-CoV-2 variants. This decision is based on a comprehensive review of the virus's evolution, the effectiveness of current vaccines, and the need for updated antigens to combat emerging variants.
The LP.8.1 antigen, identified by Nextstrain as 25A and GenBank as PV074550.1, has been shown to induce robust neutralizing antibody responses against circulating variants. This is particularly important as it demonstrates cross-reactivity with recent JN.1-descendant variants and BA.3.2, which are currently predominant in some regions. The TAG-CO-VAC's recommendation is a strategic move to ensure that vaccines remain effective against the most prevalent variants, providing continued protection against severe COVID-19 disease.
However, the TAG-CO-VAC acknowledges the limitations of the available data. There are persistent gaps in reporting cases, hospitalizations, and deaths from WHO Member States, as well as delays in genetic/genomic surveillance. This highlights the ongoing need for strengthened epidemiological and virological surveillance to monitor the emergence of new variants and their impact on public health. The group also emphasizes the importance of continued research into the immune responses and clinical endpoints of COVID-19 vaccines, particularly in diverse human populations and across different vaccine platforms.
In my opinion, the TAG-CO-VAC's recommendation for LP.8.1 as the recommended vaccine antigen is a prudent and necessary step to maintain the effectiveness of COVID-19 vaccines. However, it is crucial to address the limitations in data reporting and surveillance to ensure that future recommendations are based on comprehensive and accurate information. The ongoing work of the WHO Coronavirus Network (CoViNet) and the Global Influenza Surveillance and Response System (GISRS) is essential in this regard, as they work to bridge the gaps in our understanding of the virus's evolution and its impact on public health. Ultimately, the TAG-CO-VAC's recommendation is a testament to the organization's commitment to protecting global health and ensuring that COVID-19 vaccines remain effective against emerging variants.
